Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis

Authors: Sudheer R Thumma, Robert K Fairbanks, Wayne T Lamoreaux, Alexander R Mackay, John J Demakas, Barton S Cooke, Ameer L Elaimy, Peter W Hanson, Christopher M Lee

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Glioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal treatment approaches. However, a few patients have been reported to have long term survival greater than three years. A number of studies have attempted to define factors capable of predicting long term outcomes in specific patient groups. This article reports the outcomes of a very large group of patients diagnosed with GBM, and analyzes specific prognostic factors known to influence survival in these patients.

Methods

We used the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer Institute (NCI) to investigate various patient-related and treatment- related factors that could influence the long term survival in patients diagnosed with glioblastoma. A total of 34,664 patients aged 20 years or older with a diagnosis of GBM during the years 1973 to 2008 were studied. Overall survival outcomes were examined with Kaplan-Meier survival analysis and Cox hazard models.

Results

Asian/Pacific Islanders had a better survival compared to the white population (P = <0.001). Patients diagnosed with GBM during the years 2000 to 2008 had a superior survival rate when compared with earlier decades (P = <0 .001). Statistically significant improvements in overall survival were also found for patients who received surgical resections, and adjuvant radiation treatment versus no radiation (P-values <0.001). Young age was also found to be highly predictive of improved overall survival rates when separated into age groups as well as when studied as a continuous variable.

Conclusions

Clinical pretreatment and treatment factors, including young age at diagnosis, Asian/Pacific Islander ethnicity, recent year of diagnosis, surgical resection and the use of adjuvant radiation therapy favorably influence survival in patients diagnosed with glioblastoma.

Trial Registration

All data were obtained from the United States Surveillance Epidemiology and End Results (SEER) database.
Appendix
Available only for authorised users
Literature
1.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.CrossRefPubMed
2.
Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG, Sloan AE: Racial/ethnic differences in survival among older patients with a primary glioblastoma. J Neurooncol. 2007, 85: 171-180. 10.1007/s11060-007-9405-4.CrossRefPubMed
3.
Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung WK, Delrowe J, Coughlin CT, Mehta MP: Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol. 2011, 104: 351-356. 10.1007/s11060-010-0500-6.CrossRefPubMed
4.
Burton EC, Lamborn KR, Forsyth P, Scott J, O’Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O’Neill BP, Jenkins RB, Aldape KD: Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res. 2002, 8: 180-187.PubMed
5.
Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C: Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol. 2011, 13: 1339-1348. 10.1093/neuonc/nor133.PubMedCentralCrossRefPubMed
6.
Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993, 85: 704-710. 10.1093/jnci/85.9.704.CrossRefPubMed
7.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95: 190-198. 10.3171/jns.2001.95.2.0190.CrossRefPubMed
8.
Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Buyukberber S: Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori. 2009, 95: 191-197.PubMed
9.
Naydenov E, Tzekov C, Minkin K, Nachev S, Romansky K, Bussarsky V: Long-term survival with primary glioblastoma multiforme: a clinical study in bulgarian patients. Case Rep Oncol. 2011, 4: 1-11. 10.1159/000323432.PubMedCentralCrossRefPubMed
10.
Darefsky AS, King JT, Dubrow R: Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer. 2011, Epub ahead of print
11.
Chandler KL, Prados MD, Malec M, Wilson CB: Long-term survival in patients with glioblastoma multiforme. Neurosurgery. 1993, 32: 716-720. 10.1227/00006123-199305000-00003. discussion 720CrossRefPubMed
12.
Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999, 46: 183-188. 10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7.CrossRefPubMed
13.
Sneed PK, Prados MD, McDermott MW, Larson DA, Malec MK, Lamborn KR, Davis RL, Weaver KA, Wara WM, Phillips TL: Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery. 1995, 36: 898-903. 10.1227/00006123-199505000-00002. discussion 903–904CrossRefPubMed
14.
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64: 6892-6899. 10.1158/0008-5472.CAN-04-1337.CrossRefPubMed
15.
Robertson JT, Gunter BC, Somes GW: Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. Br J Neurosurg. 2002, 16: 562-566.CrossRefPubMed
16.
Das A, Tan WL, Teo J, Smith DR: Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neurooncol. 2002, 60: 117-125. 10.1023/A:1020622415786.CrossRefPubMed
17.
Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME: Advances in brain tumor surgery. Neurol Clin. 2007, 25: 975-1003. 10.1016/j.ncl.2007.07.006. viii–ixCrossRefPubMed
18.
Barnholtz-Sloan JS, Sloan AE, Schwartz AG: Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg. 2003, 99: 458-466. 10.3171/jns.2003.99.3.0458.CrossRefPubMed
19.
Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ: Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012, 107: 207-212. 10.1007/s11060-011-0738-7.PubMedCentralCrossRefPubMed
20.
Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B: Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integr Cancer Ther. 2004, 3: 257-261. 10.1177/1534735404267748.CrossRefPubMed
21.
Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network: Long-term survival with glioblastoma multiforme. Brain. 2007, 130: 2596-2606. 10.1093/brain/awm204.CrossRefPubMed
22.
Nieder C, Astner ST, Molls M, Grosu AL: Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol. Anticancer Res. 2007, 27: 2993-2996.PubMed
23.
Sabel M, Reifenberger J, Weber RG, Reifenberger G, Schmitt HP: Long-term survival of a patient with giant cell glioblastoma. Case report. J Neurosurg. 2001, 94: 605-611.PubMed
24.
Sacher A, Wollmann R, Kalokhe U, Munoz D, Guiot MC, Macdonald RL: Long-term survival of a patient with glioblastoma. Can J Neurol Sci. 2010, 37: 289-292.CrossRefPubMed
25.
Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P: Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009, 75: 1162-1165. 10.1016/j.ijrobp.2008.12.054.CrossRefPubMed
26.
Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D: Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002, 58: 1109-1112. 10.1212/WNL.58.7.1109.CrossRefPubMed
27.
Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, Krengli M, Maluta S, Parisi S, Bertoni F, Mantovani C, Tombolini V, De Renzis C, Lioce M, Fatigante L, Fusco V, Muto P, Berti F, Rubino G, Cipressi S, Fariselli L, Lupattelli M, Santoni R, Pirtoli L, Biti G: Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology). Neurosurgery. 2010, 67: 446-458. 10.1227/01.NEU.0000371990.86656.E8.CrossRefPubMed
28.
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011, 115: 3-8. 10.3171/2011.2.JNS10998.CrossRefPubMed
29.
Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG, Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta: Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008, 10: 79-87. 10.1215/15228517-2007-038.PubMedCentralCrossRefPubMed
30.
Allahdini F, Amirjamshidi A, Reza-Zarei M, Abdollahi M: Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival?. World Neurosurg. 2010, 73: 128-134. 10.1016/j.wneu.2009.06.001. discussion e116CrossRefPubMed
31.
Oszvald A, Guresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K: Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012, 116: 357-364. 10.3171/2011.8.JNS102114.CrossRefPubMed
32.
Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM: Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010, 6: 1591-1601. 10.2217/fon.10.123.CrossRefPubMed
33.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7.CrossRefPubMed
34.
Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S: Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009, 92: 185-191. 10.1007/s11060-008-9752-9.CrossRefPubMed
35.
Romanelli P, Conti A, Pontoriero A, Ricciardi GK, Tomasello F, De Renzis C, Innocenzi G, Esposito V, Cantore G: Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. Neurosurg Focus. 2009, 27: E8-CrossRefPubMed
36.
Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg. 1994, 81: 427-436. 10.3171/jns.1994.81.3.0427.CrossRefPubMed
37.
Gil-Benso R, Lopez-Gines C, Benito R, Lopez-Guerrero JA, Callaghan RC, Pellin A, Roldan P, Cerda-Nicolas M: Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol. 2007, 26: 224-231.CrossRefPubMed
38.
Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999, 59: 1820-1824.PubMed
39.
Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR: NFKBIA deletion in glioblastomas. N Engl J Med. 2011, 364: 627-637. 10.1056/NEJMoa1006312.PubMedCentralCrossRefPubMed
40.
Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, Kelsey KT, Patoka J, Long J, Wrensch M: Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1774-1783. 10.1158/1055-9965.EPI-05-0089.CrossRefPubMed
41.
Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Sampson JH, Chang S, Prados M, Wiencke JK, Wrensch M: IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009, 125: 680-687. 10.1002/ijc.24369.PubMedCentralCrossRefPubMed
Metadata
Title
Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis
Authors
Sudheer R Thumma
Robert K Fairbanks
Wayne T Lamoreaux
Alexander R Mackay
John J Demakas
Barton S Cooke
Ameer L Elaimy
Peter W Hanson
Christopher M Lee
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-75

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Case report

Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review

Technical innovations

A method of gastric conduit elevation via the posterior mediastinal pathway in thoracoscopic subtotal esophagectomy

Research

Effect of L-arginine supplement on liver regeneration after partial hepatectomy in rats

Case report

FDG PET/CT and MR imaging of intramuscular myxoma in the gluteus maximus

Case report

An unusual case of retrovesical ectopic prostate tissue accompanied by primary prostate cancer

Case report

Malignant epithelioid angiomyolipoma of the kidney with pulmonary metastases and p53 gene mutation